Author:
Filatova Lyubov Y.,Donovan David M.,Ishnazarova Nadiya T.,Foster-Frey Juli A.,Becker Stephen C.,Pugachev Vladimir G.,Balabushevich Nadezda G.,Dmitrieva Natalia F.,Klyachko Natalia L.
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,General Medicine,Bioengineering,Biotechnology
Reference29 articles.
1. Nelson, D. C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D. G., Dong, S., & Donovan, D. M. (2012). Endolysins as antimicrobials. Advances in Virus Research, 83, 299–365.
2. Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012). Bacteriophage endolysins as novel antimicrobials. Future Microbiology, 7(10), 1147–1171.
3. Yang, H., Yu, J., & Wei, H. (2014). Engineered bacteriophage lysins as novel anti-infectives. Frontiers in Microbiology, 5, 542.
4. Becker, S. C., Foster-Frey, J., & Donovan, D. M. (2008). The phage K lytic enzyme LysK and Lysostaphin act synergistically to kill MRSA. FEMS Microbiology Letters, 187(2), 185–191.
5. Flaherty, S. O., Coffey, A., Meaney, W., Fitzgerald, G. F., & Ross, R. P. (2005). The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. Journal of Bacteriology, 187(20), 7161–7164.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献